v3.10.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
NET REVENUE        
Total Revenue $ 69,096 $ 59,137 $ 200,266 $ 178,830
COST OF REVENUE 36,775 34,242 110,111 103,634
GROSS PROFIT 32,321 24,895 90,155 75,196
Operating expenses:        
General and administrative 21,055 18,268 59,106 53,717
Research and development 446 1,270 2,475 3,080
Sales and marketing 6,900 6,363 21,355 18,142
Loss on sale of Path Logic 0 1,058 0 1,058
Total operating expenses 28,401 26,959 82,936 75,997
Income from Operations 3,920 (2,064) 7,219 (801)
Interest expense, net 1,873 1,398 4,766 4,173
Other (income) expense (30) 0 31 0
Income (loss) before taxes 2,077 (3,462) 2,422 (4,974)
Income tax expense (benefit) 54 802 135 (30)
NET INCOME (LOSS) 2,023 (4,264) 2,287 (4,944)
Deemed dividends on preferred stock 0 912 1,950 2,734
Amortization of preferred stock beneficial conversion feature 0 1,739 3,677 5,122
Gain on redemption of preferred stock 0 0 (9,075) 0
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS $ 2,023 $ (6,915) $ 5,735 $ (12,800)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS        
Basic (in dollars per share) $ 0.02 $ (0.09) $ 0.07 $ (0.16)
Diluted (in dollars per share) $ 0.02 $ (0.09) $ 0.06 $ (0.16)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic (in shares) 87,253 79,617 87,381 79,208
Diluted (in shares) 90,899 79,617 89,925 79,208
Clinical Services        
NET REVENUE        
Total Revenue $ 59,449 $ 51,187 $ 175,960 $ 159,642
COST OF REVENUE 31,509 30,150 94,586 91,854
GROSS PROFIT 27,940 21,037 81,374 67,788
Pharma Services        
NET REVENUE        
Total Revenue 9,647 7,950 24,306 19,188
COST OF REVENUE 5,266 4,092 15,525 11,780
GROSS PROFIT $ 4,381 $ 3,858 $ 8,781 $ 7,408

Source